50,95 €
50,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
25 °P sammeln
50,95 €
50,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
25 °P sammeln
Als Download kaufen
50,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
25 °P sammeln
Jetzt verschenken
50,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
25 °P sammeln
  • Format: PDF

"COVID-19 and Omics Technologies" is a comprehensive, integrative assessment of recent information and knowledge collected on SARS-CoV-2 and COVID-19 during the pandemic based on omics technologies. It demonstrates how omics technologies could better investigate the infectious disease and propose solutions to the current concerns.

Produktbeschreibung
"COVID-19 and Omics Technologies" is a comprehensive, integrative assessment of recent information and knowledge collected on SARS-CoV-2 and COVID-19 during the pandemic based on omics technologies. It demonstrates how omics technologies could better investigate the infectious disease and propose solutions to the current concerns.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Prof. Sanjeeva Srivastava is a professor and the group leader of the Proteomics Laboratory at the Department of Biosciences and Bioengineering at the Indian Institute of Technology, Bombay. High-throughput proteomics, protein microarrays, and mass spectrometry are among his specialties. He has implemented ground-breaking AI-driven data analytics on big biological datasets. He has been at the forefront of biomedical research based on big data. His group's current research focuses on the development of clinical biomarkers for infectious diseases and malignancies. His group also pioneered therapeutic target identification efforts and decoded protein interaction networks in human illnesses like gliomas and contagious diseases like COVID-19 and malaria. His group has developed reliable diagnostic biomarkers and described the pathophysiology of severe malaria (falciparum and vivax) and COVID-19, especially the underlying mechanisms that lead to the development of severe sequelae. Dr. Srivastava is an active contributor to global proteomics research and development. He serves on the Executive Committee of Human Proteome Organization (HUPO) and Proteomics Society, India (PSI). He has more than 125 publications from his work as an independent researcher at IIT Bombay. To date, he has filed 15 patents that include biomarkers for various types of cancers, infectious diseases like malaria, leptospirosis, COVID-19, and method improvement in uncharted territories such as fish and plant proteomics.